No Data
No Data
Ocugen's Strategic Advancements and Promising Developments Justify Buy Rating
Ocugen Advances OCU200 Trial After Safety Board Review
Express News | Ocugen Inc - to Complete Phase 1 Ocu200 Trial in Second Half of 2025
Express News | Ocugen Inc - Ocu200 Shows Favorable Safety Profile, No Serious Adverse Events Reported
Express News | Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of Ocu200—a Novel Fusion Protein for Diabetic Macular Edema
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
10317752 : but dro p